Table 4

 Secondary outcome measures

Outcome measureGroupMean change from baseline(95% CI)p Value on change*Mean difference (95% CI)†p Value on difference‡
Values are mean (SD) or number (%).
NA, not applicable; FEV1, forced expiratory volume in 1 s; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; BMQ, Brief Medication Questionnaire; AQLQ, Asthma-related Quality of Life Questionnaire; CQ, Consumer Asthma Knowledge Questionnaire; PCAQ, Perceived Control of Asthma Questionnaire; reliever, short-acting β2 agonists or anticholinergic bronchodilators; preventer, inhaled corticosteroids, theophylline derivatives, cromolyns, leucotriene receptor antagonists or oral corticosteroids; LABA, long-acting β2 agonists.
*Paired t test unless otherwise noted.
†Change in intervention group – change in control group.
‡Repeated measures multivariate ANOVA unless otherwise noted.
¶ANCOVA.
§McNemar test.
**Binomial logistic regression.
Spirometry
    FEV1 (% predicted)Intervention (n = 122)−0.52 (−2.45 to 1.40)0.59−1.81 (−4.21 to 0.59)0.14
Control (n = 135)1.29 (−0.20 to 2.78)0.09
    FEV1/FVC (% predicted)Intervention (n = 122)1.39 (−0.29 to 3.08)0.100.41 (−1.76 to 2.57)0.71
Control (n = 135)0.99 (−0.41 to 2.38)0.17
Daily dose of salbutamol (μg)Intervention (n = 90)−145.4 (−263.4 to −27.3)0.02−149.1 (−283.9 to −14.4)0.03
Control (n = 92)3.8 (−62.6 to 70.1)0.91
BMQ regimen screen (range 1–7)Intervention (n = 156)−0.64 (−0.84 to −0.44)<0.01−0.44 (−0.69 to −0.18)0.04
Control (n = 173)−0.20 (−0.36 to −0.04)0.01
AQLQ (range 2–10)Intervention (n = 160)−0.64 (−0.83 to −0.45)<0.001−0.23 (−0.46 to 0.00)0.05
Control (n = 186)−0.41 (−0.55 to −0.27)<0.001
CQ (range 0–12)Intervention (n = 160)1.11 (0.80 to 1.41)<0.0011.18 (0.73 to 1.63)<0.01
Control (n = 184)−0.07 (−0.40 to 0.25)0.67
PCAQ (range 11–55)Intervention (n = 153)−2.53 (−3.36 to −1.70)<0.001−1.39 (−2.44 to −0.35)<0.01
Control (n = 176)−1.14 (−1.78 to −0.49)0.001
Percent change from baseline (95% CI) p Value on change§ Odds ratio (95% CI) p Value on odds ratio**
Correct inhaler techniqueIntervention (n = 140)48.6% (39.2% to 58.0%)<0.001NANA
ControlNANA
Asthma action planIntervention (n = 156)40.4% (31.9% to 48.9%)<0.001NANA
Control (n = 191)NANA
Adherence to preventer medicationIntervention (n = 127)16.6% (6.4% to 26.7%)<0.011.89 (1.08 to 3.30)0.03
Control (n = 121)−1.7% (−11.9% to 8.6%)0.88
Medication profile
    Intervention (n = 159)Reliever only–5.7% (−10.0% to −1.3%)0.023.80 (1.40 to 10.32)0.01
Preventer + reliever± LABA7.5% (1.8% to 9.5%)
    Control (n = 177)Reliever only0% (−3.8% to 3.8%)1.00
Preventer + reliever± LABA0% (−3.8% to 3.8%)